Michael Schotsaert
Overview
Explore the profile of Michael Schotsaert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
120
Citations
4441
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sakai A, Singh G, Khoshbakht M, Bittner S, Lohr C, Diaz-Tapia R, et al.
Mol Ther Nucleic Acids
. 2024 Oct;
35(4):102331.
PMID: 39376996
Further development of direct-acting antiviral agents against human SARS-CoV-2 infections remains a public health priority. Here, we report that an antisense peptide-conjugated morpholino oligomer (PPMO) named 5'END-2, targeting a highly...
12.
Rathnasinghe R, Chang L, Pearl R, Jangra S, Aspelund A, Hoag A, et al.
NPJ Vaccines
. 2024 Sep;
9(1):169.
PMID: 39300090
Influenza viruses pose a threat to public health as evidenced by severe morbidity and mortality in humans on a yearly basis. Given the constant changes in the viral glycoproteins owing...
13.
Vincent R, Rapoport D, Balchandani P, Borrello J, Schotsaert M, Karlicek R, et al.
Res Sq
. 2024 Aug;
PMID: 39108476
Respiratory interventions including noninvasive ventilation, continuous positive airway pressure and high-flow nasal oxygen generated infectious aerosols may increase risk of airborne disease (SARS-CoV-2, influenza virus) transmission to healthcare workers. We...
14.
Park S, Wiest M, Yan V, Wong P, Schotsaert M
Hum Vaccin Immunother
. 2024 Jul;
20(1):2368288.
PMID: 38953250
Many pathogens enter the host through mucosal sites. Thus, interfering with pathogen entry through local neutralization at mucosal sites therefore is an effective strategy for preventing disease. Mucosally administered vaccines...
15.
Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Pache L, et al.
Nature
. 2024 Jun;
631(8019):E3.
PMID: 38890463
No abstract available.
16.
Slamanig S, Gonzalez-Dominguez I, Chang L, Lemus N, Lai T, Luis Martinez J, et al.
EBioMedicine
. 2024 Jun;
105:105185.
PMID: 38848648
Background: In order to prevent the emergence and spread of future variants of concern of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), developing vaccines capable of stopping transmission is crucial....
17.
Jangra S, Lamoot A, Singh G, Laghlali G, Chen Y, Ye T, et al.
Front Immunol
. 2024 May;
15:1370564.
PMID: 38711520
There are considerable avenues through which currently licensed influenza vaccines could be optimized. We tested influenza vaccination in a mouse model with two adjuvants: Sendai virus-derived defective interfering (SDI) RNA,...
18.
Fernandez J, Marin A, Rosales R, Penrice-Randal R, Mlcochova P, Alvarez Y, et al.
Biochim Biophys Acta Mol Basis Dis
. 2024 Apr;
1870(5):167193.
PMID: 38648902
SARS-CoV-2 infection can cause severe pneumonia, wherein exacerbated inflammation plays a major role. This is reminiscent of the process commonly termed cytokine storm, a condition dependent on a disproportionated production...
19.
Laghlali G, Wiest M, Karadag D, Warang P, OKonek J, Chang L, et al.
bioRxiv
. 2024 Apr;
PMID: 38586014
Current COVID-19 mRNA vaccines delivered intramuscularly (IM) induce effective systemic immunity, but with suboptimal immunity at mucosal sites, limiting their ability to impart sterilizing immunity. There is strong interest in...
20.
Losada A, Izquierdo-Useros N, Aviles P, Vergara-Alert J, Latino I, Segales J, et al.
J Immunol
. 2024 Feb;
212(8):1307-1318.
PMID: 38416036
Plitidepsin is a host-targeted compound known for inducing a strong anti-SARS-CoV-2 activity, as well as for having the capacity of reducing lung inflammation. Because IL-6 is one of the main...